GlobeNewsWire
03 Jul 2026, 22:10 UTC · 2h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
3 claims · each scored for market impact
The NIAID has issued a Notice of Termination for Convenience regarding Appili Therapeutics' contract for the VXV-01 fungal vaccine candidate. — The loss of a government contract for a specific vaccine candidate reduces guaranteed funding and signals a setback for that specific pipeline asset.
-0.60Appili is focusing on the ATI-1801 program, which is eligible for a Priority Review Voucher (PRV). — PRVs have significant market value as they can be sold to other biotech firms for substantial sums, providing a potential high-value liquidity event.
+0.40The company continues to generate royalty revenue from its commercial portfolio via LIKMEZ®. — Existing commercial revenue provides a baseline of financial stability that offsets some of the risk from terminated development contracts.
+0.20Which stocks this story touches
Continue reading
6 related stories
Top 2 movers · tap to explore
The company received a notice of termination for a government contract supporting its VXV-01 fungal vaccine candidate.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
GlobeNewsWire
4h ago
